In 207 adults with primary immune thrombocytopenia, subcutaneous efgartigimod PH20 did not beat placebo on the primary endpoint (platelets >=50x10^9/L at 4 of 6 visits in weeks 19-24; 17/124 vs 11/68; p=0.51) or secondary endpoints; it was well tolerated.
RCTn = 207
Cooper et al. Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial